Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Richard Porter

Associate Professor (Biochemistry)


I completed my undergraduate degree in Biochemistry at Trinity College. This was followed by a Ph.D. with Prof. John M. Scott in the area of carbon-one metabolism and a three year postdoctoral position at the Department of Biochemistry University of Cambridge UK with Prof. Martin D. Brand. I was subsequently awarded a Health Research Board (HRB)Fellowship based in Prof. Clive William's laboratory in Trinity. Dr. Porter's research focuses on understanding mammalian energy metabolism. His research achievements are based ideas founded in solid science, a substantial grant base, the quality of the researchers that he recruits, the advanced technology in the laboratory and his collaborations with prominent international laboratories, both academic and industrial. I have been a lecturer and Principal Investigator in Trinity since 1997, was appointed Director of Teaching and Learning in the School of Biochemistry & Immunology (Postgraduate) from 2004-2008 & 2016-2017, was elected for two terms as Head of Biochemistry from 2011-2017, and was elected Fellow of Trinity College Dublin since 2007. I have over 60 publications in peer reviewed scientific journals and currently has over €0.5M in research grants. I am an editor with a leading Elsevier Journal (Biochimica Biophysica Acta-Bioenergetics) and am regularly invited to give lectures at Conferences, Universities and Research Institutes. I teach many aspects of biochemistry to scientists, medical students, pharmacists at all levels within the University and has received a Provost Teaching Award commendation. I am on the management committee of several International Scientific Societies, including the European Bioenergetics Conference. I regularly participates in scientific outreach projects such as the "Fat" exhibition in the Science Gallery. My research has resulted in the discovery of the nature of the "speed gene" in Thoroughbred horses [https://www.rte.ie/news/2018/1106/1008968-race-horses/][https://www.irishtimes.com/news/science/irish-scientists-pinpoint-what-makes-thoroughbred-racehorses-go-faster-1.3688584] and I am an inventor on the World's First Nutrigenomic Product for Thoroughbred Horses, now sold as EnerGene-Q10 by Plusvital[http://www.tcd.ie/news_events/articles/world-s-first]. Furthermore, in addition to basic research grants from Science Foundation Ireland, The Health Research Board, Teagasc and Trinity, I have an Enterprise Ireland Innovation Partnership Programme grant in collaboration with Plusvital and Funding from Artelo plc. I also acted a consultant for Price Waterhouse Coopers in the area of R&D Tax Credits.
  (HUMAN)   (RAT LIVER)   (SKELETAL MUSCLE)   Ageing, memory and other cognitive processes   Analytical Techniques   Basic Skills Education   Biochemistry, Carbohydrates   Biochemistry, Lipids   Biochemistry, metabolism   Biochemistry, Proteins   BODY-MASS   BOVINE   BRAIN   BROWN-ADIPOSE-TISSUE   Diabetes & Obesity   Diabetes and diabetic complications   Drug discovery   Energy Chemical Sciences   EQUINE   Immune system   Innate immunology   Life Sciences   Lipids, steroids, membranes   Membrane Transport   Membrane transport, structure and dynamics   Metabolic Biology   Metabolism and metabolic diseases   Mitochondria   Neuroscience   ORAL-CANCER   OXYGEN CONSUMPTION   Photosynthesis   Proteins, enzymology and protein engineering   Thermal Effects
 Cellular Biology of Fatty Acid Binding Proteins (FABPs) Inhibition In Cancer
 Development of an in vitro model of cachexia
 Exploitation of a Novel in vitro Skeletal Muscle Cell System to Develop New Nutritional Products for the Thoroughbred Horse
 Assessment of the Energetic Benefits of Plusvital Supplements/Nutrients on Thoroughbred Horses
 Energy Metabolism in Oral Cancers

Page 1 of 3
Details Date
Representative for Ireland on the European Bioenergetics Conference Committee 2004-present
Representative for Ireland on the International Union of Biochemists and Molecular Biologists (IUBMB) Nominating Committee 2012-2014
Representative for Ireland on the MITOEAGLE COST Action 2016 -2020
Representative for Ireland on the MITOFOOD COST Action 2005-2009
Chairman of European Bioenergetics Conference 2008 (EBEC 2008)[www.tcd.ie/Biochemistry/ebec2008/][ebec2008@tcd.ie] 2008
Ireland Representation on the COST B10 'Brain Damage and Repair' group. 2000-2004
External examiner in Biochemistry to medical students in University College Cork 2015-2020
On the Editorial Board of Biochimica Biophysica Acta (Bioenergetics) Elsevier 2008-present
External examiner in Biochemistry & Molecular Biology, Dublin Institute of Technology (DIT) Cathal Brugha street 2009-2013
External examiner in Biochemistry to medical students Royal College of Surgeons, Ireland (RCSI). 2006
External examiner in Biochemistry to medical students University College Dublin (UCD) 2006
External examiner in Biochemistry to medical students Queens University belfast (QUB) 2006
Member of the Peter Mitchell Medal Awarding Committee 2008-2012
Language Skill Reading Skill Writing Skill Speaking
French Basic Basic Basic
Details Date From Date To
Appointed to the Bioenergetics and Metabolism Theme Panel III of the Biochemical Society. 2022 2026
Member of the British Immunology Society 2021 present
Editor of Elsevier's Biochimica Biophysica Acta (Bioenergetics) 2008 present
Member of The European Bioenergetics Conference Committee 2004 present
Member of the Irish Area Section of the Biochemical Society 2006 present
Member of the The UK Biochemical Society 1986 present
Treasurer of the Irish Area Section of the Biochemical Society (IASBS) 2009 2012
Member of the International Society for Oxygen Transport in Tissues (ISOTT) 2007 2008
Appointed to the Bioenergetics and Metabolism Theme Panel III of the Biochemical Society. 2004 2007
The British Society of Immunology 2021 present
John Noone, Marilena Karavyraki, Mary F. Rooney, Andrew Yates, Saoirse E. O'Sullivan, Richard K. Porter., A Role for Cannabinoids in Preventing Cachexia in an in vitro Human Muscle Cell Model., https://www.eventsforce.net/biochemsoc/frontend/reg/absViewDocumentFE.csp?documentID=3539&eventID=130, Drug Repurposing II, London, May 2022, edited by UK Biochemical Society , 2022, Notes: [https://www.eventsforce.net/biochemsoc/frontend/reg/absViewDocumentFE.csp?documentID=3539&eventID=130], Conference Paper, PUBLISHED
Richard K. Porter, Is there a role for Interleukin-6 (IL-6) in Cancer Metabolism? - Evidence of a role for Interleukin-6 in anoikis resistance and bioenergetic programming in oral squamous cell carcinoma, European Society of Clinical Investigation (ESCI), Bari, Italy., June, 2022, Piero Portincasa, Invited Talk, PUBLISHED
Richard Porter, A Role for Cannabinoids in Preventing Cachexia in an in vitro Human Muscle Cell Model, Drug Repurposing II,, London, Feb 2022, 2022, UK Biochemical Society, Invited Talk, PUBLISHED
Richard K. Porter, A comparison of bioenergetics in human tongue pre-cancerous dysplastic oral keratinocytes and squamous cancer cells, Bioblast 2022: BEC Inaugural Conference, Innsbruck, Austria, June, 2022, Erich Gnaiger, Invited Talk, PUBLISHED
Mary Rooney, Nuno Neto, Michael Monaghan, Emmeline Hill, Richard K. Porter, Conditionally immortalised equine skeletal muscle cell lines for in vitro analysis, Biochemistry and Biophysics Reports, 2022, Journal Article, PUBLISHED
Marilena Karavyraki, Richard K. Porter, Evidence of a role for interleukin-6 in anoikis resistance in oral squamous cell carcinoma., Medical Oncology, 39, 2022, p60-, Notes: [doi: 10.1007/s12032-022-01664-5.], Journal Article, PUBLISHED  DOI
Marilena Karavyraki, Erich Gnaiger, Richard K. Porter, Bioenergetics in human tongue pre-cancerous dysplastic oral keratinocytes and squamous cancer cells, Bioenergetics Communications (BEC), (2022), 2022, Notes: [: https://www.bioenergetics-communications.org/index.php/bec/article/view/karavyraki_2022], Journal Article, PUBLISHED  DOI
ZQ Ge, RK Porter, MF Rooney , COMPARASION OF PHENOTYPES ASSOCIATED WITH A HIGHLY INVASIVE TRIPLE-NEGATIVE BREAST CANCER (TNBC) CELL LINE AND ITS PARENTAL COUNTERPART , 12th International Cancer Conference 2022 Meeting Abstracts, 12th International Cancer Conference 2022 , TBSI, Oct 2022, 2022, Meeting Abstract, PUBLISHED
Maloney BT, Kubisztal M, Karavyraki M, Rooney MF, Knox A and Porter RK, The Potential of Nicotinamide N-Methyltransferase (NNMT) as an Anti-Cancer Target in Cultured Human Oral Squamous Cancer Cells (OSCC), Irish Association of Dental Research (IADR) Conference, IADR International Division Meeting Abstract, Irish Association of Dental Research (IADR) Conference, IADR International Division, Chengdu, China, June 2022, 2022, Notes: [Delivered online Winner First Prize], Oral Presentation, PUBLISHED
Salma Mohammed Ajahdali , Modulation of hepatic autophagy for therapeutic correction of type 2 diabetes, Trinity College Dublin, 2022, Thesis, PUBLISHED
  

Page 1 of 19

  

Award Date
Shortlisted for Knowledge Ireland (KTI) Award. http://www.knowledgetransferireland.com/KTI%20Impact%20Awards/ 2018
Awarded commendation for Teaching by Trinity College Dublin (Provosts' Teaching Award) July 2014
Lucker-Cobbe Award
Fellow of Trinity College Dublin 2007
1. Over the last two years we have established an in vitro model of human skeletal muscle cachexia (muscle wastage due to cancer). In collaboration with Artelo plc, a NASDAQ quoted company, we have identified a synthetic cannabinoid analogue that can prevent cachexia in human muscle. This drug is now in human Phase 1b/2a clinical trials (Cancer Appetite Recovery Study (CAReS)). Manuscripts are in preparation, with UK Biochemical Society meeting abstract and press report already released (April 2022). 2. We elucidated the biochemical basis of the crucial performance defining myostatin polymorphism in Thoroughbred Horses. Essentially, we discovered why certain Thoroughbred horses are born to be sprinters. In addition, we uncovered a metabolic difference between endurance and sprint Thoroughbred Horses which resulted in us patenting the discovery through TCD & UCD, and us getting a licence to use that IP to grant the company PlusVital to produce the product [World's First Nutrigenomic Product for Thoroughbred Horses, now sold as EnerGene-Q10 by Plusvital]. 3. The majority of my research career has focused on the molecular basis of metabolic rate, a research area that has direct implications for understanding physiology and for developing anti-obesity strategies. I have demonstrated that mitochondrial inefficiency accounts for one fifth our resting metabolic rate and factors, such as body size, that determine metabolic rate also effect mitochondrial efficiency. 3. Cancer Metabolism: We have recently identified, for the first time, IL-6 as a protagonist in metastasis/anoikis resistance and metabolic/mitochondrial programming in oral cancer, while demonstrating the IL-6 receptor is a potential target for therapy. We have also elucidated anti-cancer target data for (a) neuroblastoma cancers (b) mesothelioma and non-small lung cancer cells (c) breast cancer cells. Another, project is looking at the role of intracellular Fatty Acid Binding Proteins (FABPs) on cancer cell phenotype in brain cancer.